Sign up online today & collaborate
or click here to find out more
Biotecnol Limited and Cancer Research UK (CRUK), have anounced that an experimental immuno-oncology treatment will move into early phase clinical trials for patients with advanced solid tumours, including lung cancers, under a collaboration agreement between Cancer Research UK and Biotecnol Limited.
Cancer Research UK will support the early clinical development of the company’s promising first-in-class drug called Tb535H.
The drug is the first to emerge from Biotecnol’s novel antibody development platform, Trisoma®. It is directed against the 5T4/WAIF1 tumour antigen, a protein found on many different solid tumours and is thought to contribute to the spread of cancer cells.
Tb535H recruits the patient’s T-cells –killer cells of the immune-system – and directs them to attack tumours. This highly targeted approach uses the patient’s own immune system to fight cancer.
The WAIF1 antigen was discovered by scientists at the Cancer Research UK Manchester Institute. It could be a valuable target in many different cancer types, but the initial focus in this trial will be to treat cancers with high unmet-need.This includes thoracic cancers such as mesothelioma, small-cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC), for which survival remains very low, and renal cell carcinoma.
Under the agreement, Biotecnol and Cancer Research UK’s Centre for Drug Development will collaborate to take forward Tb535H through a Biotecnol-sponsored first-in-man Phase I clinical trial, using Cancer Research UK’s drug development expertise in return for shareholdings in Biotecnol.
Pedro de Noronha Pissarra, chief executive officer of Biotecnol said: “We’re very proud to work with Cancer Research UK on the development of advanced clinical trial approaches in this competitive and highly promising field of immuno-oncology.
“The collaboration is important for Biotecnol’s strategy of working with top cancer institutions in the immune-oncology field which will accelerate the development of cutting-edge therapeutic approaches to fight cancer.”
Dr Nigel Blackburn, Cancer Research UK’s director of drug development, said: “It’s hugely exciting to be able to accelerate the development of a drug that could change outcomes for patients with many different types of cancer.
“In particular we urgently need new ways to improve treatment for lung cancer, which causes more than one in five of all cancer deaths in the UK.
“Without this collaboration it might have been years before this treatment reached patients so we‘re pleased to work with Biotecnol to elevate their novel drug development platform.”
About Biotecnol Limited
Biotecnol Limited is an immuno-oncology company developing innovative immune-function activating and immune-function modulation approaches for treating cancer. These approaches seek to recruit or to modulate the body’s own immune defences such as T cells and NK cells to kill tumours. Biotecnol multi-specific antibody products are based on its proprietary Tribody™ and Trisoma® platforms, which are comprised of a variety of formats with key properties. Under the Trisoma® platform, Biotecnol has developed a novel format known as Targeted T-cell Engaging Agonistic Response Modifiers or iChecks™.These products aim at improving tumour cell dependent T-cell or NK-cell activation. The iCheck™ formats are expected to achieve a more localized immune-function activation and obtain less or no systemic toxicity, whilst having an increased therapeutic index.These are potentially safer and more effective drugs for treating highly-heterogeneous and highly-aggressive solid tumours.
About Cancer Research UK’s Centre for Drug Development
Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development, formerly the Drug Development Office, has been pioneering the development of new cancer treatments for 25 years, taking over 140 potential new anti-cancer agents into clinical trials in patients. It currently has a portfolio of around 30 new anti-cancer agents in preclinical development, Phase I or early Phase II clinical trials. Six of these new agents have made it to market including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. Two other drugs are in late development Phase III trials. This rate of success is comparable to that of any pharmaceutical company.
About Cancer Research UK
> Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
> Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
> Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public.
> Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
> Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
> Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
> Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.